ApexMind
ApexMind Raises $50M Series B to Transform Biotech
Quick Facts
ApexMind Raises $50M Series B in Latest Funding Round
ApexMind has successfully closed a $50M Series B funding round, marking a significant milestone in the company's growth trajectory. The round was led by Greylock Partners, with participation from Accel.
Company Overview
Founded in 2025 and headquartered in Boston, MA, ApexMind has established itself in the Biotech space. Leading machine learning platform automating enterprise workflows with advanced AI models
With a current valuation of $250M, the company has demonstrated strong market traction and investor confidence.
Investment Details
- Amount Raised: $50M Series B
- Valuation: $250M
- Lead Investor: Greylock Partners
Future Outlook
As ApexMind moves forward with its expanded funding, the company is well-positioned to capitalize on market opportunities and drive innovation in the biotech space.
Key Investors
About the Author
Related Company Reports
PrimeNet Raises $300M Series C to Transform Biotech
PrimeNet has secured $300M Series C in funding to accelerate growth and innovation. Leading machine learning platform automating enterprise workflows with advanced AI models...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...